Browse News
Filter News
Found 12,943 articles
-
CEO Emma Walmsley projects that the British biopharma’s Arexvy sales will exceed £1 billion in its first year on the market, leaving Pfizer’s Abrysvo respiratory syncytial virus vaccine far behind in the race.
-
Innovent Presents Clinical Data Update of IBI351 (KRAS G12C Inhibitor) Monotherapy in Lung Cancer and Colorectal Cancer at ESMO Asia Congress 2023
12/1/2023
Innovent Biologics, Inc. announces the publication of updated clinical data of IBI351 monotherapy in non-small cell lung cancer and colorectal cancer at the European Society for Medical Oncology Asia Congress 2023, held during December 1-3 in Singapore.
-
Innovent's MSCI ESG Rating Upgraded to A
11/30/2023
Innovent Biologics, Inc. announces that the Company has been upgraded to 'A' according to Morgan Stanley Capital International's latest ESG rating, ranking at the forefront of the biotechnology industry.
-
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
11/30/2023
Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today closing of its collaboration deal to co-develop and co-commercialize asset TEV ‘574 with Sanofi (EURONEXT: SAN and NASDAQ: SNY).
-
Deals, Dupixent and GLP-1 drug shortages
11/29/2023
This week on The Weekly we talk struggles with GLP-1 drug shortages and what that might mean for Novo and Lilly competitors; Regeneron and Sanofi positive results for Dupixent in COPD. Plus, Merck buys Caraway, Beigene's deal with Ensem, ups and downs for Flagship. -
Keep up with the regulator’s latest rulings on novel drugs and expanded indications, as the second half of 2023 promises some major milestone FDA approvals.
-
Vaxcyte Appoints Jacks Lee to Board of Directors
11/28/2023
Vaxcyte, Inc. today announced the appointment of Jacks Lee to its Board of Directors.
-
New data show the biologic significantly reduced exacerbations in chronic obstructive pulmonary disease, confirming positive results from an earlier trial.
-
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
11/27/2023
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the second Dupixent® investigational Phase 3 chronic obstructive pulmonary disease trial showed that Dupixent significantly reduced exacerbations, confirming positive results from the landmark Phase 3 BOREAS trial.
-
Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
11/27/2023
The second Dupixent® investigational Phase 3 chronic obstructive pulmonary disease trial has shown that Dupixent significantly reduced exacerbations, confirming positive published results from the landmark Phase 3 BOREAS trial.
-
Innate Pharma to Host Virtual KOL Event on Lacutamab
11/27/2023
Innate Pharma SA announced that it will host a virtual KOL event on lacutamab, a first-in-class anti-KIR3DL2 antibody currently in development for cutaneous T-cell lymphoma and peripheral T cell lymphoma, on Tuesday, December 12, 2023, at 7:00AM PST.
-
China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351
11/24/2023
Innovent Biologics, Inc. announces that the New Drug Application for IBI351 has been accepted by the Center for Drug Evaluation of the National Medical Products Administration of China and granted Priority Review designation[1], for the treatment of patients with advanced non-small cell lung cancer harboring KRAS G12C mutation who have received at least one systemic therapy.
-
Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart
11/23/2023
Simcere Pharmaceutical Group Limited entered into an exclusive license and collaboration agreement with Connect Biopharma HongKong Limited in relation to Rademikibart, an innovative IL-4Rα monoclonal antibody.
-
Pfizer and BioNTech scored a win over Moderna on Tuesday as the European Patent Office decided that a key patent held by the Massachusetts biotech related to its COVID-19 vaccine is invalid.
-
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care
11/22/2023
Innovent Biologics, Inc. announces that full results from a Phase 2 clinical trial of mazdutide, a glucagon-like peptide-1 receptor and glucagon receptor dual agonist, in Chinese patients with type 2 diabetes were published in Diabetes Care.
-
Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Accepted the New Drug Application for Taletrectinib (ROS1 Inhibitor)
11/22/2023
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801) and AnHeart Therapeutics ("AnHeart") announce that the New Drug Application (NDA) for taletrectinib, has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have been previously treated with ROS1 TKIs.
-
AnHeart Therapeutics and Innovent Announce China’s NMPA Has Accepted a New Drug Application for Taletrectinib (ROS1 Inhibitor)
11/22/2023
AnHeart Therapeutics and Innovent Biologics, Inc. today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted a New Drug Application (NDA) for taletrectinib, a next-generation ROS1 tyrosine kinase inhibitor (TKI).
-
C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment
11/20/2023
C4 Therapeutics, Inc. today announced the appointment of Owen Hughes to its board of directors.
-
Sobi to present new data at ASH 2023 Annual Meeting
11/20/2023
Sobi® will present new data at the 65th Annual Meeting of the American Society of Hematology in San Diego from the 9th to the 12th of December 2023.
-
Q32 Bio and Homology Medicines Announce Merger Agreement
11/16/2023
Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Homology Medicines, Inc., announced they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.